Both BCL2 and BCL-XL are overexpressed in several cancers and contribute to tumor cell survival and therapy resistance by preventing apoptosis in response to DNA damage, oxidative stress, or cytotoxic treatments. The gene discussed is BCL2L1; the disease is neoplasm.